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Breast cancer is a genetically and clinically heterogeneous disease,
and the contributions of different target cells and different onco-
genic mutations to this heterogeneity are not well understood.
Here we report that mammary tumors induced by components of
the Wnt signaling pathway contain heterogeneous cell types and
express early developmental markers, in contrast to tumors in-
duced by other signaling elements. Expression of the Wnt-1 pro-
tooncogene in mammary glands of transgenic mice expands a
population of epithelial cells expressing progenitor cell markers,
keratin 6 and Sca-1; subsequent tumors express these markers and
contain luminal epithelial and myoepithelial tumor cells that share
a secondary mutation, loss of Pten, implying that they arose from
a common progenitor. Mammary tumors arising in transgenic mice
expressing -catenin and c-Myc, downstream components of the
canonical Wnt signaling pathway, also contain a significant pro-
portion of myoepithelial cells and cells expressing keratin 6. Pro-
genitor cell markers and myoepithelial cells, however, are lacking
in mammary tumors from transgenic mice expressing Neu, H-Ras,
or polyoma middle T antigen. These results suggest that mammary
stem cells andor progenitors to mammary luminal epithelial and
myoepithelial cells may be the targets for oncogenesis by Wnt-1
signaling elements. Thus, the developmental heterogeneity of
different breast cancers is in part a consequence of differential
effects of oncogenes on distinct cell types in the breast.
Transgenic (TG) activation of different oncogenic pathways inmouse mammary glands induces tumors with different gene
expression profiles and histopathological features (1–8). The
mouse mammary tumor virus (MMTV) promoter usually used
to regulate these transgenes is expressed in a diverse population
of mammary cells (9, 10). Therefore, cells at different develop-
mental stages may undergo tumorigenesis as a result of the
activation of different oncogenic pathways.
It has been difficult to define the precise lineage of target cells
of breast cancer because of the lack of animal models expressing
oncogenes in specific mammary progenitors. However, studies in
the epidermis and the hematopoietic system have demonstrated
that cancers that arise from stem or progenitor cells usually
express markers of the originating cells (11, 12). Thus, the
presence of stem or progenitor cell markers in mammary tumors
may suggest that tumors arose from immature cells. Two genes,
keratin 6 and stem cell antigen 1 (Sca-1), appear to be prefer-
entially expressed in mammary stem andor progenitor cells.
Keratin 6 is expressed in mammary gland anlage at embryonic
day 16.5 (ref. 13 and J.M.R., unpublished observations) and in
some of the body cells in the terminal end buds (TEBs); but
keratin 6 is not found in the highly proliferative cap cells (14, 15)
and rarely in cells in the mature ducts and differentiated alveoli
(15), consistent with the distribution of progenitor cells. In
addition, keratin 6 is associated with the arrested state of
differentiation observed in the mammary ducts from CEBP-
null mice (13). Sca-1, encoded by Ly-6AE, is a GPI-linked
protein also found in hematopoietic stem cells (16); it is ex-
pressed on the surface of a population of mammary cells
enriched for stem cells and present in TEBs (17). Depletion of
Sca-1-positive cells results in a loss of functional stem cells in
mammary gland reconstitution experiments (17). Although re-
tained in a population of more mature ductal cells, Sca-1 is not
observed after cells have further differentiated to express the
progesterone receptor (17).
Here we report that keratin 6 and Sca-1 cells are observed in
mammary tumors induced by the Wnt-1 signaling pathway,
which has been implicated in proliferation and maintenance of
undifferentiated cells in several tissue types, including the mam-
mary gland (18–28), but not in tumors induced by oncogenes
affecting other pathways. In addition, we provide other evidence
to suggest that ectopic activation of the Wnt pathway may target
these undifferentiated mammary progenitors for tumorigenesis.
Materials and Methods
Mice. TG mice expressing MMTV-Wnt-1 (29), MMTV--catenin
(30), MMTV-c-Myc (31), MMTV-Neu (32), MMTV-H-Ras (33),
or MMTV-PyMT (34) have been described, as have mice har-
boring targeted inactivating mutations of Pten (35). MMTV-
Wnt-1 TG mice were a mixture of FVB, SJL, and C57BL6
strains; Pten mutant mice were a mixture of FVBN, 129, and
C57BL6 strains; all others were in a pure FVBN background.
Tissue Processing and Immunocytochemistry. Tissues were fixed and
processed as described (36). Immunohistochemistry was per-
formed by using Vector ABC and MOM kits (Vector Labora-
tories) according to the manufacturer’s recommendations and
as described (35). The following antibodies were used: purified
rabbit antibodies against mouse keratin 6 (Covance, Princeton)
and Pten (NeoMarkers, Fremont, CA); purified mouse mono-
clonal antibodies against -smooth muscle actin (SMA, Dako)
and against BrdUrd (BD Biosciences Immunocytometry Sys-
tems, product no. 347580); and partially purified rat antibodies
against keratin 8 (37, 38), purchased from the Developmental
Studies Hybridoma Bank, Iowa City, organized under the aus-
pices of the National Institute of Child Health and Human
Development and maintained by the University of Iowa. To label
cells in S-phase of cell cycle, BrdUrd (Sigma, product no.
B-5002) at 100 g per gram of body weight in saline was injected
i.p. 1 h before mice were killed.
Abbreviations: FACS, fluorescence-activated cell sorting; LOH, loss of heterozygosity;
MMTV, mouse mammary tumor virus; SMA, smooth muscle actin; TEB, terminal end bud;
TG, transgenic.
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Southern Hybridization and Western Analysis. Tumor DNAs were
digested with PstI and processed for Southern blotting by using
a [32P]dCTP-labeled probe made from a 0.9-kb template located
in intron 5 of Pten as described (36). For Western blotting,
tumors were ground to powder in liquid nitrogen and lysed by
boiling in the sample-loading buffer for acrylamide gel electro-
phoresis. Protein lysates were resolved in 10% polyacrylamide
gels containing SDS and transferred to nitrocellulose mem-
branes. After incubating with rabbit antibodies against Pten
(NeoMarkers, 1:1,000) or mouse monoclonal antibodies against
-tubulin (Sigma, 1:5,000), the specific reaction was visualized by
peroxidase-conjugated secondary antibodies (Roche) and a
chemiluminescent substrate (SuperSignal, Pierce).
Flow Cytometry. Mammary cells and tumors were isolated by
using collagenase as described (17). After incubating with FITC-
conjugated rat IgG against Sca-1 (BD Pharmingen, product no.
553336, 106 cells per g), f luorescence-activated cell sorting
(FACS) was performed as described (17).
Results
Keratin 6 and Sca-1 Are Expressed in Preneoplastic and Neoplastic
Mammary Lesions Induced by Components of the Wnt Signaling
Pathway but Not by Neu, Ras, and PyMT. While carrying out
experiments designed to identify genes differentially regulated in
the evolution of mammary tumors in MMTV-Wnt-1 TG mice
(S.H., unpublished work), we discovered that both keratin 6 and
Sca-1 are more highly expressed in hyperplastic mammary glands
and tumors from MMTV-Wnt-1 TG mice than in non-TG virgin
mammary glands (Fig. 6, which is published as supporting
information on the PNAS web site), suggesting that Wnt-1-
induced mammary tumors may originate from progenitor cells.
To confirm this observation, we used immunohistochemical
staining to identify keratin 6-expressing cells. In non-TG mam-
mary glands, keratin 6 was detected in some body cells within the
terminal end buds (TEBs) and occasionally in mature luminal
epithelial cells (Fig. 1 B and D), consistent with previous reports
(14, 15). However, in MMTV-Wnt-1 TG mice, we found keratin
6 in a greater number of ductal cells, usually in enlarged ducts,
in a heterogeneous pattern (Fig. 1 A and C). Many of the stained
cells are in the luminal layer, but some of them have invaded into
the lumen (Fig. 1 A). Ducts that were not stained were usually
smaller in diameter and did not appear to be hyperplastic (Fig.
1C). Because transgenes regulated by MMTV are known to be
expressed in heterogeneous patterns in the mammary gland (9,
39–42), the keratin 6-negative ducts may not express the
MMTV-Wnt-1 transgene.
The mammary cells in adult MMTV-Wnt-1 TG mice have a
greater rate of proliferation than those in non-TG virgin mice,
as measured by immunohistochemical staining for cells labeled
with BrdUrd and for cells expressing Ki-67, another proliferation
marker (data not shown). It is therefore possible that the
expansion of keratin 6-positive cells in the mammary glands of
MMTV-Wnt-1 TG mice may result from an increased proportion
of proliferating cells. Indeed, keratin 6 has been associated with
hyperproliferation in the suprabasal layer in the skin (43). To
determine whether the increased expression of keratin 6 is an
oncogene- or proliferation-induced effect in the mammary
gland, we compared mammary glands from adult MMTV-Wnt-1
TG virgins with proliferating mammary glands from mid-
pregnancy non-TG mice. Similar numbers of BrdUrd-stained
cells (Fig. 1 E and F) and Ki-67-positive cells (data not shown)
were detected in virgin TG and pregnant non-TG mammary
glands. However, only a few cells per field were stained with
anti-keratin 6 antibodies in the pregnant non-TG mice (data not
shown). Taken together, these results suggest that aberrant
Wnt-1 expression arrests differentiation of mammary cells at an
early phase and stimulate their proliferation and that prolifer-
ation per se is not associated with expression of keratin 6.
We also used immunohistochemistry to confirm the microar-
ray results suggesting that keratin 6 is also expressed in mammary
tumors from MMTV-Wnt-1 TG mice. Strong, although not
uniform, staining for keratin 6 was observed in Wnt-1-induced
tumors (Fig. 2A). To determine whether the observed expansion
of keratin 6-positive cells is unique to the MMTV-Wnt-1 TG
model, we stained sections of mammary glands and tumors from
a number of other TG models. Interestingly, keratin 6-positive
cells were abundant in both mammary gland and tumor sections
from MMTV--catenin and MMTV-c-Myc TG mice, but keratin
Fig. 1. Keratin 6-positive cells are expanded in hyperplastic mammary glands
from MMTV-Wnt-1 TG mice. Immunohistochemical staining was used to de-
tect keratin 6 (A–D) or BrdUrd (E and F) in mammary gland sections from
MMTV-Wnt-1 TG mice that were 3-week-old (A) or 3-month-old (C and E)
virgins, from non-TG females that were 3 weeks old (B), 3 months old (D), or
in mid-pregnancy (F). The hyperplastic keratin 6-positive cells projecting into
the lumen are indicated by an arrowhead (A). The insert in D is a 4-fold higher
view of the site denoted with an arrowhead. Staining for BrdUrd, as repre-
sented by arrows, demonstrates similar levels of proliferation in mammary
glands from MMTV-Wnt-1 TG virgin (E) and wild-type mid-pregnancy (F) mice.
Cell types are indicated by arrows in A and B; scale bars are shown in each
panel.
Fig. 2. Keratin 6-positive cells in mammary tumors arising in TG mice
expressing components of the Wnt signaling pathway. Keratin 6 was detected
by immunohistochemical staining of tumors from mice carrying the indicated
MMTV TG. The scale is shown in F.
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6-positive cells were not detected in premalignant glands or
tumors from MMTV-Neu, MMTV-H-Ras, or MMTV-PyMT TG
mice (Fig. 2 and Fig. 7, which is published as supporting
information on the PNAS web site), implying a transgene-
specific effect on the expansion of keratin 6-positive cells with
keratin 6 expressed in tumors induced by components of the Wnt
signaling pathway. These results confirm that keratin 6 is not a
by-product of proliferation, because the frequency of replicating
cells is high in mammary tumors from all these TG mice, as
evidenced by staining for Ki67 (data not shown).
We used FACS to confirm and extend the microarray data in
Fig. 6 showing that Sca-1, a second marker for progenitor cells,
was expressed in Wnt-1-induced hyperplasias or tumors. About
50% of the mammary cells from the hyperplastic mammary
glands and from mammary tumors from virgin MMTV-Wnt-1
TG mice were positive for Sca-1 (Fig. 3 A and B). In contrast,
20% of mammary cells from non-TG virgin or pregnant mice
were positive, consistent with our earlier report that Sca-1
antibody labels progenitor cells, in addition to a subset of
partially differentiated cells (17). Furthermore, 10% of cells
from MMTV-Neu or MMTV-PyMT TG mice were positive. To
determine whether keratin 6 and Sca-1 are expressed in the same
cells, we stained mammary cells prepared from hyperplastic
mammary glands and tumors from MMTV-Wnt-1 TG mice with
anti-Sca-1 antibodies, separated Sca-1-positive and Sca-1-
negative cells by FACS, and stained them with antibodies against
keratin 6 (Fig. 3C). Approximately 10% of Sca-1-positive cells
were positive for keratin 6 (data not shown), whereas keratin 6
was not detected in Sca-1-negative cells.
Myoepithelial and Luminal Epithelial Tumor Cells Coexist in MMTV-
Wnt-1 TG Mice but Not in Neu, H-Ras, or PyMT TG Mice. Tumors
arising from stem or progenitor cells may show mixed lineage
differentiation (11). To investigate whether tumors from
MMTV-Wnt-1 TG mice may contain transformed myoepithelial
cells (the normal type of which constitutes the outer layer of
normal mammary ducts) in addition to transformed luminal
epithelial cells (which comprise the majority of human and
transgene-induced murine mammary carcinomas), we stained
their sections for both keratin 8, a marker for luminal epithelial
cells (44), and -SMA, which is expressed in myoepithelial cells
and pericytes in non-TG mammary glands (ref. 45 and data not
shown). The number of -SMA-positive cells was high, approx-
imately equal to the number of keratin 8-positive cells (Fig. 4).
Keratin 14, another marker for myoepithelial cells (46), was also
found in the -SMA-positive subset of cells (data not shown).
These results suggest that the Wnt-1-induced tumors are com-
posed of two predominant cellular components, luminal epithe-
lial and myoepithelial cells, consistent with the findings of
Rosner et al. (2) and Cui and Donehower (49).
Because the -SMA-positive cells are pleomorphic, hyperpro-
liferative, disorganized, and present in large quantities (Fig. 4 A
and C), they are probably neoplastic cells rather then benign cells
recruited to the tumor mass. The presence of myoepithelial cells
was also observed in mammary tumors from MMTV--catenin
or MMTV-c-Myc TG mice, but not in those from MMTV-Neu,
MMTV-H-ras, or MMTV-PyMT TG mice (Fig. 8, which is
published as supporting information on the PNAS web site),
similar to the report by Rosner et al. (2). However, in contrast
to the plump abnormal myoepithelial cells detected in tumors
from MMTV-Wnt-1 TG mice, the myoepithelial cells in -cate-
nin- and c-Myc-induced tumors were more elongated and well
organized, forming a single layer around the keratin 8-positive
tumor cells, as in normal ducts.
Loss of Pten Occurs in Both Luminal Epithelial and Myoepithelial Cells
in Wnt-1-Induced Mammary Tumors. In previous studies, we found
that the wild-type allele of Pten was undetectable in the majority
Fig. 3. Increased proportions of Sca-1-positive cells in hyperplastic mammary
glands and mammary tumors from MMTV-Wnt-1 TG mice. Representative
FACS histograms (A) and a summary bar graph (B) representing data from
three to five independent FACS experiments are shown for mammary glands
from wild-type virgin and mid-pregnancy mice, hyperplastic mammary glands
from MMTV-Wnt-1 TG mice, and mammary tumors from TG mice carrying
MMTV-Wnt-1, MMTV-Neu, or MMTV-PyMT transgenes. Hyperplastic cells or
tumor cells prepared from MMTV-Wnt-1 TG mice were stained with anti-Sca-
1-FITC, sorted by FACS, and stained for keratin 6 (C). Red indicates positive
staining for keratin 6. Images were captured by using a 40 objective.
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of Wnt-1-induced mammary tumors arising in a Pten heterozy-
gous background (36); an expanded set of samples is shown in
Fig. 5A. Because such tumors, like Wnt-1-induced tumors in a
wild-type Pten background, are composed approximately equally
of luminal epithelial and myoepithelial cells (Fig. 8), loss of
heterozygosity (LOH) must have occurred in both cell types.
We confirmed the absence of Pten protein by both Western
blotting and immunohistochemical staining, using a purified
rabbit antibody specific for Pten (Fig. 5 B and C). By Western
blotting, Pten was detected in tumors from Pten-wild-type,
MMTV-Wnt-1 TG mice and in tumors from MMTV-Wnt-1
TGPten/ mice without LOH; but Pten was almost undetect-
able in mammary tumors that were MMTV-Wnt-1 TGPten/
with LOH at the Pten locus (Fig. 5B). In accord with the results
of the Western blotting, by immunohistochemical staining, Pten
was undetectable in both luminal epithelial and myoepithelial
tumor cells in MMTV-Wnt-1 TGPten/ mammary glands that
had undergone LOH (Fig. 5C Lower and ref. 36). On the other
hand, Pten was readily detected in stromal cells within and
outside of the tumor and in hyperplastic ducts surrounding the
tumor. Pten was also detected in most or all cells in tumors from
Wnt-1 TGPten/ mice (Fig. 5C Upper). Together, these results
strongly suggest that the loss of Pten occurs in both luminal
epithelial and myoepithelial cells of tumors arising in MMTV-
Wnt-1 TGPten/ mice. Because it is unlikely that the two cell
types sustained independent mutations, a single event most likely
occurred in a common progenitor to these cells.
Discussion
In this study, we present several lines of evidence to support a
role for mammary progenitor cells in mammary tumorigenesis
induced by Wnt signaling. First, many keratin 6-positve cells are
present in both preneoplasias (Fig. 1) and tumors (Fig. 2) from
MMTV-Wnt-1 TG mice. Second, keratin 6-positive hyperplastic
and tumor cells in these mice also express Sca-1 (Fig. 3C). Third,
Fig. 5. Loss of Pten heterozygosity in both luminal epithelial and myoepi-
thelial cells of mammary tumors from Pten/, MMTV-Wnt-1 TG mice. (A)
Southern blotting analysis for LOH at the Pten locus in mammary tumors from
MMTV-Wnt-1 TG mice; the Pten genotypes are indicated above the panel.
Fragments of the wild-type (WT) and target mutant alleles of Pten are indi-
cated by arrowheads. The image is a composite of two independent blots
(lanes 1–5 and lanes 6–8). (B) Western blotting analysis for Pten in MMTV-
Wnt-1-derived mammary tumors; the Pten genotype and LOH status are
indicated above the panel. The image of the same blot after a subsequent
incubation with antibodies against -tubulin is also shown to indicate varia-
tions in amounts of protein loaded. The faint signal in the samples with
evidence of LOH is most likely due to protein from the stroma. (C) Immuno-
histochemical staining for Pten in mammary tumors; the genotype is indicated
above each panel. Areas of tumor (T) and hyperplastic (H) ducts are indicated.
The string of positively stained cells (indicated by an arrow) probably repre-
sents stroma recruited into the tumor. The scale is shown in Lower.
Fig. 4. Abnormal myoepithelial cells in mammary tumors from MMTV-Wnt-1
TG mice. Consecutive paraffin sections of a mammary tumor from an MMTV-
Wnt-1 TG mouse were stained for -SMA and keratin 8 as indicated. Note the
large nuclei and disorganization of the -SMA-positive cells in the tumor (C).
The scales are shown in each panel.
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luminal epithelial and myoepithelial cells coexist in these tumors,
suggesting transformation of a common precursor. Finally, in
some mammary tumors arising in Pten heterozygous, MMTV-
Wnt-1 TG mice, the wild-type Pten locus is missing in both
luminal epithelial and myoepithelial cells (Fig. 5), suggesting that
loss of Pten occurred in a common precursor to these two
populations of tumor cells. Efforts are underway to attempt to
define a subset of tumor cells from MMTV-Wnt-1 TG mice
capable of cancer regeneration, in light of a recent report (47)
that only a small number of human breast cancer cells have the
capacity to regenerate tumors in immunodeficient mice.
Mammary tumors from MMTV--catenin and MMTV-c-Myc
mice, which express components of the Wnt signaling pathway,
are similar to tumors from MMTV-Wnt-1 TG mice. Collectively,
our data suggest that deregulated Wnt signaling causes excess
proliferation of mammary progenitor cells and predisposes them
to cancer. This interpretation is consistent with reports that loss
of Wnt signaling blocks early mammary development (25, 26),
and it is also consistent with the role of Wnt signaling in other
tissues. Wnt signaling is now known to play a critical role in the
proliferation of hematopoietic stem cells and those in the skin,
colon, and other organs (18–28), and deregulated activation of
this pathway is a cancer-predisposing factor in several tissues
including the colon, skin, and liver (19, 48).
Although progenitor cells are the likely precursors to cancer
in mammary glands that have activated the Wnt signaling
pathway, keratin 6 andor Sca-1 are not present in mammary
hyperplasias and tumors from several other TG lines, including
MMTV-Neu, MMTV-H-Ras, and MMTV-PyMT TG mice (Figs.
2 and 7). In addition, a detectable second tumor cell type, such
as myoepithelial tumor cells, is absent in these tumors (Fig. 8).
These results are consistent with previous reports that initiating
genetic lesions exert a significant influence on both gene ex-
pression patterns and histological features of mammary tumors
from both humans and TG animals (1–8). However, our findings
also suggest that the differentiation status of putative target cells
may contribute to the heterogeneity of breast cancer. There are
several possible mechanisms by which target cells may influence
the histopathology and molecular features of tumors resulting
from different oncogenes. Transgenes encoding Neu, H-Ras,
and PyMT may transform progenitor cells, but either fail to
arrest them at the progenitor stage or actively induce differen-
tiation of the transformed cells. Alternatively, Neu, H-Ras, and
PyMT may be able to transform only more differentiated cells
that no longer express keratin 6 or Sca-1. In addition, there is a
remote possibility that different oncogene RNAs expressed from
MMTV are differentially translated in progenitor and differen-
tiated cells. Finally, we cannot rule out the possibility that all of
these oncogenes transform differentiated cells, but Wnt-1 sig-
naling leads to dedifferentiation; however, the loss of Pten in
both myoepithelial and luminal epithelial cells argues strongly
against this possibility.
Although it remains to be determined whether the Wnt-1
signaling pathway and the oncogenic pathways mediated by Neu,
H-Ras, and PyMT induce tumors in mammary cells at precisely
the same stage of differentiation, these transgenes are presum-
ably expressed in similar populations of mammary cells, because
they are all under the control of the MMTV LTR. In accord with
this assumption, interbreeding of MMTV-c-Myc and MMTV-
H-Ras led to more rapid formation of mammary tumors (33); but
differentiation markers have not been studied in these tumors to
ask whether the H-Ras- or c-Myc-induced phenotype predomi-
nates. To ask this question in a different context, we have
recently bred MMTV-Wnt-1 with MMTV-Neu TG mice. The
resulting bi-TG females develop mammary tumors as early as 12
weeks of age, sooner than in mice carrying either transgene
alone, implying that both transgenes were expressed in these
tumors (K.P. and Y.L., unpublished work). Interestingly, neo-
plastic cells in these tumors are positive for keratin 6, Sca-1, and
myoepithelial markers, and they are histopathologically more
similar to Wnt-1-induced tumors than to Neu-induced tumors
(K.P. and Y.L., unpublished work). Therefore, it appears that
Neu does not relieve the arrest of differentiation that may be
imposed by Wnt-1 signaling in mammary progenitor cells.
In conclusion, we provide several lines of evidence to suggest
that components of the Wnt signaling pathway transform mam-
mary progenitors, and that these cells develop into heteroge-
neous tumors containing different histological cell types express-
ing markers of both mature and immature epithelial cells. Thus,
breast cancer heterogeneity may result from transformation of
distinct cell types by different oncogenes.
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